Our History

M2Gen: Rooted in Science and Cancer Research

M2Gen was spun out of the Moffitt Cancer Center, a world-class cancer research institute, to help facilitate a collaborative approach to the fight against cancer. Founded in 2006, M2Gen’s efforts are not only disrupting the way industry researchers look for new cancer therapies, but also developing what the future holds for their approach toward precision cancer medicines.

M2Gen is a rapidly growing company, and we have raised $75 million to grow our product offerings and scale our capabilities to serve our partners.

woman-reading-tablet-screen

The M2Gen Timeline

timeline-desktop

Our Leadership

M2Gen is led by industry trailblazers and experienced scientific experts who share the belief that the future of effective cancer research and development is rooted in collaboration.

Management Team

Photo of Helge Bastian, PhD, CEO of M2Gen

Helge Bastian, PhD

President and Chief Executive Officer of M2Gen

See Full Bio

Helge Bastian, PhD, currently serves as the president and chief executive officer of M2Gen. Dr. Bastian joins M2Gen from Thermo Fisher Scientific, Inc., where he led the Sample Preparation and Synthetic Biology businesses as Vice President & General Manager since 2014. Before Thermo Fisher Scientific, Dr. Bastian held a number of senior leadership positions and served as a member of several executive leadership teams, including Managing Director and Chief Commercial Officer at Indivumed, an integrated oncology company; Vice President Global Marketing, Business Development and Strategy at Sigma-Aldrich (now Merck KGaA); Executive Vice President Life Science Services for SGS, the world’s leading inspection, verification, testing and certification company. Prior to SGS, he held various management positions during his 11-plus years at Qiagen including Vice President Molecular Diagnostics, Vice President Global Strategic Marketing, and Vice President PreAnalytiX, a QIAGEN / Becton Dickinson joint venture. Dr. Bastian earned his diploma in biology / biochemistry from Georg-August University and holds a Ph.D. in molecular and cell biology performed at the Max-Planck Institute for Biophysical Chemistry. From 2014-2018, Dr. Bastian served as a board member to the International Gene Synthesis Consortium (IGSC). Dr. Bastian has recently been appointed to the board of directors at enzymatic gene synthesis pioneer Molecular Assemblies, Inc., San Diego, and is an alumnus from the Max-Planck-Network and the Columbia Business School.

William (Bill) S. Dalton, PhD, MD

William (Bill) S. Dalton, PhD, MD

Founder and Executive Chair of the Board of M2Gen

See Full Bio

Dr. William (Bill) S. Dalton is founder and executive chair of the board of M2Gen. He is the former CEO of M2Gen (2012-2017) and past president, CEO, and center director of Moffitt Cancer Center, an NCI-designated Comprehensive Cancer Center (2002-2012). During his tenure as CEO of Moffitt, he led the development of the Total Cancer Care program and the creation of the Health Research Informatics platform, designed to follow patients throughout their lifetime. He holds several patents in the areas of precision medicine and computer networking. In 2014, Moffitt Cancer Center, in partnership with the James Cancer Center at Ohio State University, founded the cancer center alliance called ORIEN, the Oncology Research Information Exchange Network, with the goal of accelerating cancer research discovery by sharing information and delivering hope through collaborative learning and partnerships.

Joseph R. Smith, CPA, CGMA

Joseph R. Smith, CPA, CGMA

Senior Vice President and Chief Financial Officer of M2Gen

See Full Bio

Joseph R. Smith, CPA, CGMA, currently serves as the senior vice president and chief financial officer for M2Gen. In this role, Joe is responsible for the financial, marketing, and sales aspects of M2Gen and provides leadership for the day-to-day financial and operational aspects of the business. Prior to joining M2Gen, Joe served as chief operating officer and chief financial officer for Bisk Education and was the CFO, secretary, and treasurer for a private, then public, dental practice management company. Joe started his career in public accounting at Deloitte, rose to the level of partner, and was in charge of the middle market practice in the Tampa, Florida office. He holds a BSBA in Accounting with Honors from University of Florida.

Judy Barkal

Judy Barkal

Vice President and Chief Technology / Medical Informatics Officer of M2Gen

See Full Bio

Judy Barkal currently serves as the vice president and Chief Technology and Medical Informatics Officer at M2Gen. She brings deep experience in strategy, innovation, and complex business and technology transformation. Judy’s most recent role was head of Information Strategy and Innovation at Knight Cancer Institute, Oregon Health and Science University. At OHSU, Judy established a cancer informatics strategic roadmap and, as PI, led the creation of a clinical data repository integrated with genomics data to serve multiple cancer researchers and programs. Judy was previously a partner at IBM Global Business Services, where she led complex business and technology transformations globally in financial services, healthcare, energy, and retail. Prior to IBM, Judy specialized in clusters and high-performance computing at Sequent Computer Systems. In her early career, she developed safety-critical, real-time flight control systems at Rockwell Collins.

Odalys Capote

Odalys Capote

Vice President and Chief Administrative Officer of M2Gen

See Full Bio

Odalys Capote currently serves as vice president/chief administrative officer at M2Gen and administrator for the Oncology Research Information Exchange Network (ORIEN) at M2Gen. She also serves as administrator of the DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center. Odalys has over 30 years of experience in healthcare, including such roles as chief of staff, compliance and privacy officer, cost accounting/decision support implementation, project management, and consulting. She holds a Bachelor’s degree in Marketing from the University of South Florida School of Business.

M2GenManagementTeamPhoto_GaryOliver

Oliver Hampton, PhD

Vice President, Bioinformatics and Biostatistics of M2Gen

See Full Bio

Oliver Hampton, PhD, currently serves as the vice president of Bioinformatics and Biostatistics for M2Gen. Oliver leads the bioinformatics team and is building the biostatistics team to support the Avatar project, as well as collaborative projects between M2Gen, Pharma and ORIEN partners. Oliver comes to M2Gen with great expertise in Next-Generation-Sequencing, having led the Platform Informatics team, Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center. Prior to that, Oliver was an Assistant Professor at Baylor College of Medicine.

Stan Micek

Stan Micek

Vice President and Chief Commercial Officer of M2Gen

See Full Bio

Stan brings to M2Gen significant life sciences experience, including leadership roles within multiple aspects of the branded and generic pharmaceutical product value chain, new business ventures, and negotiation of several large corporate transactions.

Prior to joining M2Gen, Stan served as the director, Oncology Commercialization at the Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James). From 2014 to 2016, Stan was the Director of Licensing for Ohio State University’s (OSU) Technology Commercialization Office. Prior to joining OSU, Stan held executive roles within 2 mid-sized pharmaceutical companies (Xanodyne Pharmaceuticals and AAIPharma) leading their corporate/ business development functions, specifically in- and out-licensing, acquisitions, and divestitures.

For over 19 years at Abbott Laboratories, he held positions of increasing responsibility in several functional areas, including national account sales, marketing, business development and licensing, engineering, and international manufacturing/ operations.

Stan earned his BS in chemical engineering from the Illinois Institute of Technology in Chicago and his MBA in marketing and international management from Northwestern University’s Kellogg Graduate School of Management in Evanston, IL.

Board of Directors

William (Bill) S. Dalton, PhD, MD

Executive Chair of the Board - M2Gen

See Full Bio

Dr. William (Bill) S. Dalton is founder and executive chair. He is the former CEO of M2Gen (2012-2017) and past president, CEO, and Center Director of Moffitt Cancer Center, an NCI-designated Comprehensive Cancer Center (2002-2012). During his tenure as CEO of Moffitt, he led the development of the Total Cancer Care program and the creation of the Health Research Informatics platform, designed to follow patients throughout their lifetime. He holds several patents in the areas of precision medicine and computer networking. In 2014, Moffitt Cancer Center, in partnership with the James Cancer Center at Ohio State University, founded the cancer center alliance called ORIEN, the Oncology Research Information and Exchange Network, with the goal of accelerating cancer research discovery by sharing information and delivering hope through collaborative learning and partnerships.

Timothy J. Adams

President (Retired) - Time Customer Service, Inc.

See Full Bio

Tim is the former President of Time Customer Service, Inc. (TCS) and was responsible for all TCS activities conducted on behalf of Time Inc.  TCS employs 700+ people and occupies in excess of 300,000 square feet of office and light industrial space.  TCS’s primary responsibility is the fulfillment of subscriptions for the Time Inc. family of magazines, the National Geographic Society, American Express, Kiplinger, National Wildlife, Wenner Media, Foreign Affairs, Smithsonian, and The Week. 
 
TCS mails approximately 360 MM laser printed promotions per year.  In-bound mail processing volumes are about 21 MM transactions annually.  In addition to mail, TCS handles in excess of 7 MM in-bound telephone customer service calls.  Mr. Adams is from Webster Springs, West Virginia and received his B.S. in Industrial Engineering from West Virginia University.

James M. Asher

Senior Vice President, Chief Legal & Development Officer - Hearst

See Full Bio

James M. Asher is the senior vice president and chief legal and development officer of Hearst. He joined Hearst in October 1997. He is a member of the board of directors of Hearst and Fitch Group and is a testamentary trustee under the will of William Randolph Hearst. Previously, he served as managing partner and chairman of the executive committee of Rogers & Wells, an international law firm.

As chief legal officer, Asher has general responsibility for all of Hearst's legal affairs. As chief development officer, he is engaged with Hearst's senior operating management in new ventures, acquisitions, and internal business development efforts.

Asher joined Rogers & Wells in 1974 after graduating from New York University School of Law with a JD. He was named a partner of the law firm in 1981, was appointed the firm's managing partner in 1990, and became chairman of the executive committee in 1994.

Helge Bastian, PhD

President and Chief Executive Officer - M2Gen

See Full Bio

Helge Bastian, PhD, currently serves as the president and chief executive officer of M2Gen. Dr. Bastian joins M2Gen from Thermo Fisher Scientific, Inc., where he led the Sample Preparation and Synthetic Biology businesses as Vice President & General Manager since 2014. Before Thermo Fisher Scientific, Dr. Bastian held a number of senior leadership positions and served as a member of several executive leadership teams, including Managing Director and Chief Commercial Officer at Indivumed, an integrated oncology company; Vice President Global Marketing, Business Development and Strategy at Sigma-Aldrich (now Merck KGaA); Executive Vice President Life Science Services for SGS, the world’s leading inspection, verification, testing and certification company. Prior to SGS, he held various management positions during his 11-plus years at Qiagen including Vice President Molecular Diagnostics, Vice President Global Strategic Marketing, and Vice President PreAnalytiX, a QIAGEN / Becton Dickinson joint venture. Dr. Bastian earned his diploma in biology / biochemistry from Georg-August University and holds a Ph.D. in molecular and cell biology performed at the Max-Planck Institute for Biophysical Chemistry. From 2014-2018, Dr. Bastian served as a board member to the International Gene Synthesis Consortium (IGSC). Dr. Bastian has recently been appointed to the board of directors at enzymatic gene synthesis pioneer Molecular Assemblies, Inc., San Diego, and is an alumnus from the Max-Planck-Network and the Columbia Business School.

Gregory Dorn, MD, MPH

President - Hearst Health

See Full Bio

Greg Dorn is the president of Hearst Health, overseeing FDB (First Databank), Zynx Health, MCG, and Hearst Health International, and serves as a director of Homecare Homebase MedHOK, M2Gen, Hearst Health Ventures, and the Hearst Health Innovation Lab.

The mission of the Hearst Health network is to help guide the most important care moments by delivering vital information into the hands of everyone who touches a person’s health journey. Each year in the US, care guidance from the Hearst Health network reaches 84% of discharged patients, 177 million insured individuals, 60 million home health visits, and 3.1 billion dispensed prescriptions.

For more than 2 decades, Dorn has been focused on raising the standard of excellence for patient care across the healthcare spectrum, through clinically rigorous guidance delivered by efficient, scalable technology. He is the co-inventor of 2 patented healthcare software technologies that continue to be used in health systems across the US. His expertise is in developing and commercializing inventive and disruptive solutions that improve care quality and efficiency.

Dorn has held a variety of leadership positions across Hearst, including chief operating officer of Zynx Health and president of FDB. In 2013 he was appointed an executive vice president of Hearst Business Media and continues to serve in that role. He is also a vice president of Hearst.

Dorn received his medical doctorate from the Columbia University College of Physicians and Surgeons and his bachelor's degree from the Columbia University School of Engineering. He performed his clinical training at UCLA, where he also obtained his master’s degree in health services management.

Alan List, MD

President and CEO - Moffitt Cancer Center

See Full Bio

Dr. Alan List is the president and chief executive officer of Moffitt Cancer Center in Tampa, FL.

Dr. List is internationally recognized for his many contributions in the development of novel, more effective treatment strategies for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). His pioneering work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which went on to receive fast-track designation from the US Food and Drug Administration and approval for the treatment of patients with MDS and multiple myeloma. This work transformed the natural history of MDS from a premalignant condition that progressed to malignancy requiring aggressive treatment to a condition managed in the outpatient setting with oral agents.

Prior to his current position, Dr. List served as executive vice president and physician-in-chief, the vice deputy physician-in-chief, and the chief of the Malignant Hematology Division at Moffitt, where he holds the Morsani Endowed Chair.

Before coming to Moffitt in 2003, Dr. List was a professor of medicine at the University of Arizona, Tucson, where he also served concurrently as the director of the Leukemia and Blood and Marrow Transplant Program and director of the Division of Translational/Clinical Research Program.

After earning a medical degree in 1980 from the University of Pennsylvania, Philadelphia, Dr. List completed an internship and residency in internal medicine at the Good Samaritan Medical Center in Phoenix, Arizona. He then completed fellowships in hematology and medical oncology at Vanderbilt University Medical Center in Nashville, Tennessee.

Dr. List has received peer-reviewed NIH support for his work and publishes extensively in the areas of MDS and acute leukemia, authoring more than 350 peer-reviewed manuscripts, chapters, and books. He lectures nationally and internationally and has received several awards in recognition of his seminal contributions such as the Aplastic Anemia & MDS International Foundation Leadership in Science Award (2014); induction into The Joshua Lederberg Society (2009); the Emil J. Freireich Award for Clinical Research, MD Anderson (2006); the JP McCarthy International Prize for Advancing the Body of Scientific Knowledge in Myelodysplastic Syndrome (2004); and the General Motors Cancer Research Foundation Merit Award (1991).

He serves as a member of the Myelodysplastic Syndrome Foundation board of directors and is the president-elect (2017-18) for the Society of Hematologic Oncology. He also is an active member of the American Society of Clinical Oncology; American Society of Hematology; American Association for Cancer Research; and the Southwestern Oncology Group.

Frederick J. Lynch

Chief Executive Officer and President (Retired) - Masonite International Corporation

See Full Bio

Prior to his retirement in June of 2019 Frederick J. Lynch (Fred) served as President and CEO of Masonite International (NYSE:DOOR) for 12 years. Masonite is a leading global manufacturer of residential and commercial doors employing more than 10,000 employees providing the highest value door products to customers in more than 70 countries around the world. During his tenure Fred led the company through the historic housing recession, restructuring the company and capital structure which eventually led to an IPO of the firm on the NYSE in 2013.

Fred joined Masonite from Alpharma, a global pharmaceutical company, where he served as President of the Human Generics Division and Senior Vice President of Global Supply Chain for the corporation before leading the sale of 75% of the company to Actavis Pharmaceuticals. Prior to joining Alpharma in 2003, Fred’s career spanned 18 years at Honeywell International (formerly AlliedSignal), most recently as Vice President and General Manager of the Specialty Chemical Business. He began his career at AlliedSignal as a shift foreperson in a chemical manufacturing plant and subsequently held various roles in manufacturing and general management.

Fred is a native of the Bronx, New York. He received a B.S. in Chemical Engineering from Villanova University and an M.B.A in Finance from Temple University. Fred and his wife, Ruth, reside in Tampa and have a daughter and son who are twins.

Fred serves on the board of Ingevity corporation, a specialty chemical firm trading on the NYSE (NGVT). He is a member of the Moffitt Cancer Center Foundation Board in Tampa Florida, and is Vice Chairman of the Institute Finance and Strategy Committee. Fred was a founding director of the Michael Lynch Memorial Foundation, a non-profit organization that continues to provide college scholarships to children of firefighters and victims of 9/11 (www.Mlynch.org).

Richard P. Malloch

President - Hearst Business Media

See Full Bio

Richard P. Malloch is the president of Hearst Business Media. He joined Hearst in 1991 as deputy group head of Hearst’s Consumer Book Publishing and Trade Magazine Group. In the late 1990s, Hearst sold the consumer book business (William Morrow and Avon Books) to HarperCollins. Malloch looked to reinvest the proceeds from the sale and built a fifth large operating group for Hearst. Traditionally, Hearst’s trade publishing was based on print products with significant revenue generated from advertising. Malloch changed the strategy and business model, moving the Group toward revenue generated from subscriptions and licensing fees. In consideration of this new strategy, the Group was renamed Hearst Business Media. Today, the business is nearly 100 percent digital.

In addition to his role as president of Hearst Business Media, Malloch is a senior vice president of Hearst and a member of the board of directors.

Hearst Business Media focuses on the financial, healthcare, and transportation industries. Business Media wants to become indispensable to its customers. It enjoys very high (over 90 percent) renewal rates and has gained the confidence of many of its customers as seen by long-term (7- to 10-year) license agreements.

Hearst Business Media has shown substantial growth in the past 10 years. Internal growth and product enhancements have been coupled with acquisitions to make Business Media a significant contributor to Hearst’s financial performance. Hearst Business Media has become the second-largest contributor to Hearst—contributing more operating income than the traditional consumer media businesses Hearst is best known for. Key investment acquisitions include: Fitch Group, CAMP Systems International, MedHOK, Homecare Homebase, MCG, and Zynx Health.

Prior to joining Hearst, Malloch served as a principal in the New York office of Morgan Stanley & Co., where he was involved in corporate finance and merger and acquisitions. Malloch has devoted most of his professional life to working with companies in the communications and technology industries. He was actively involved in expanding the Morgan Stanley media franchise to include: cable television, cellular telephone, entertainment, and information technologies. Malloch also helped to develop the media practice in Europe and Asia.

Malloch began his career as a member of the policy staff to the assistant secretary of the US Department of Energy in Washington, DC.

Allan Martin

Co-Founder and Chief Executive Officer - Lumina Analytics

See Full Bio

Allan S. Martin co-founded Lumina Analytics in 2015 and now serves as chief executive officer for the company. Mr. Martin is also chairman of Atlantic Merchant Capital Investors, a private merchant bank in Tampa, Florida founded in 2009. Additionally, he is the managing partner of Fleur De Lis Partners.

Allan Martin is the chairman of Moffitt Medical Group board of directors. Mr. Martin is also a trustee of Tampa Jesuit High School and is chairman of the Martin Family Foundation. Prior to Lumina and Atlantic Merchant Capital Investors, Mr. Martin was chief executive officer of MCS Holdings, the nation's second-largest mortgage field services firm from 2003 to 2009. He was a founder and advisory board member of USAmeriBank from 2006 to 2010. Mr. Martin started his career with Deloitte & Touche following the receipt of a Bachelor of Science degree from the University of Southern Maine. Allan and his wife, Marie, live in Tampa and have 3 children.

Thomas Sellers, PhD, MPH

Center Director & Executive Vice President - Moffitt Cancer Center & Research Institute

See Full Bio

Dr. Sellers completed his undergraduate studies in community nutrition at the University of California Davis, his PhD in epidemiology from Tulane University in 1988, and completed post-doctorate training in statistical genetics training at Louisiana State University the following year. He then joined the University of Minnesota School of Public Health faculty, where he attained tenure and served as associate director of their cancer center. In 1998 he joined the Mayo Clinic Cancer Center. He served as deputy director from 2002 until he left to join Moffitt.

Dr. Thomas Sellers is director of the Cancer Center and the Moffitt Research Institute and executive vice president. He previously served as associate center director of Cancer Prevention and Control. He joined Moffitt in August 2003.

Studying the functional changes associated with cancer reflects the interaction of genetic and environmental factors. Dr. Sellers is using epidemiology and molecular genetics to sort out this complex interplay and inform better methods for prevention and clinical management.

Dr. Sellers is the author of more than 340 peer-reviewed original manuscripts that have been published in journals such as Cancer, New England Journal of Medicine, American Journal of Epidemiology, JAMA, Cancer Research, and Nature Genetics. He has garnered more than $45M in grant support as principal or co-principal investigator from the National Cancer Institute. Dr. Sellers serves as a reviewer on several editorial boards, including the Journal of Clinical Oncology and Frontiers in Applied Genetic Epidemiology, and is deputy editor for Cancer Epidemiology Biomarkers and Prevention. Dr. Sellers has been invited to present at over 50 national and international events, including in Nijmegen, the Netherlands; Tianjin, China; Stockholm, Sweden; London, England, Heidelberg, Germany; and Shanghai, China.

Board Observers

Raphael Pollock, MD, PhD, FACS

Director, the Ohio State University Comprehensive Cancer Center Kathleen Wellenreiter Klotz Chair in Cancer Research

See Full Bio

Raphael E. Pollock, MD, PhD was born in Chicago, IL in 1950. He is a graduate of Oberlin College in Oberlin, OH, where he majored in history. This was followed by medical school at St. Louis University, St. Louis; MO, residency training in general surgery at Rush-Presbyterian-St. Luke’s Medical Center and the University of Chicago Hospitals and Clinics, Chicago, IL; followed by fellowship training in surgical oncology at the University of Texas MD Anderson Cancer Center, Houston, TX. Dr. Pollock was invited to join the MD Anderson faculty in 1984 upon completion of fellowship training. While serving as an assistant professor of surgery, Dr. Pollock began graduate studies at the University of Texas Health Science Center/Houston, Graduate School of Biomedical Sciences, culminating in receipt of the PhD in tumor immunology in 1990. In 1993 Dr. Pollock began service as chairman of the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, a position that he held until 2010. In 1996, service as head of the Division of Surgery at the University of Texas MD Anderson Cancer Center was begun, a position entailing supervisory relationships with all 7 surgical specialty departments at that institution. In 2013 Dr. Pollock was recruited to Ohio State University as professor and director of the Division of Surgical Oncology and Chief of Surgical Services at the James Comprehensive Cancer Center. This was followed by appointment in 2015 as Surgeon in Chief, the James Comprehensive Cancer Center and Surgeon in Chief, the Ohio State University Health System. In 2017, Dr. Pollock was appointed to his current position as professor and director of the Ohio State University Comprehensive Cancer Center.

Dr. Pollock’s clinical and laboratory research work focuses on soft tissue sarcoma, a rare tumor system of connective tissue origin. He has been the recipient as principal investigator of an NIH/NCI K08 Clinician-Investigator Award (1984-89), an NIH/NCI R29 FIRST Award (1989-1994), an NIH/NCI R01 Award (1995-2007), and NIH/NCI T32 Training Grant (1999-2010), and an NIH/NCI SPORE award (2012-2017). He is married to Dina Lev, MD, a Professor of Surgery at Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel. They have 5 children: Jessica, a medical student at the Ohio State University College of Medicine; Samuel and Eden, students at the Ohio State University College of Arts and Sciences; and Noam and Omer, who are in high school in Tel Aviv, Israel.

Steve Swartz

President and Chief Executive Officer - Hearst

See Full Bio

Steven R. Swartz became president and chief executive officer of Hearst, one of the nation's largest diversified media, information, and services companies, on June 1, 2013, having worked for the company for more than 20 years and having served as its chief operating officer since 2011.

Hearst's major interests include ownership in cable television networks such as A&E, HISTORY, Lifetime, and ESPN; majority ownership of global ratings agency Fitch Group; Hearst Health, a group of medical information and services businesses; 30 television stations such as WCVB in Boston and KCRA in Sacramento; newspapers such as the Houston Chronicle, San Francisco Chronicle, and Albany Times Union; more than 300 magazines around the world, including Cosmopolitan, ELLE, Harper’s Bazaar, and Car & Driver; digital services businesses, such as iCrossing and KUBRA; and investments in emerging digital and video companies, such as Verizon Hearst Media Partners, Complex, BuzzFeed, VICE, and AwesomenessTV.

Swartz, 55, is a member of the Hearst board of directors, a trustee of the Hearst Family Trust, and a director of the Hearst Foundations.

He was president of Hearst Newspapers from 2009 to 2011 and executive vice president from 2001 to 2008. From 1995 to 2000, Swartz was president and chief executive of SmartMoney, a magazine venture launched by Hearst and the Wall Street Journal in 1991 with Swartz as founding editor. Under his leadership, SmartMoney magazine won 2 National Magazine Awards and was Advertising Age’s Magazine of the Year.

Swartz began his career in 1984 as a reporter with the Wall Street Journal after graduating from Harvard. He served as an editor on the Journal's Page One staff from 1989 to 1991.

Swartz is chairman of the Associated Press and a member of the board of directors of ESPN and Lincoln Center for the Performing Arts, where he is also chairman of the Lincoln Center Corporate Fund and co-chairman of the Lincoln Center Business Advisory Council. He is a trustee of New York-Presbyterian Hospital, vice chairman of the Partnership for New York City, and a member of the Business Roundtable.

Interested in Joining the M2Gen team?

Learn More